MAPT and Alzheimer disease: Clinical trials targeting Aβ have yielded disappointing results and consequently, the focus of AD therapeutic approaches has turned to the elimination of toxic tau forms through the use of anti-tau antibodies or antisense oligonucleotides26–35.